← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biofluidica, Inc
San Diego, CA
$7,166,251
Total funding
9
Grants
Funding over time
peak $1.6M · FY2010–20$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,166,251 · 9
By mechanism
R44$4,749,949 · 3
R43$1,216,912 · 4
N44$999,873 · 1
N43$199,517 · 1
Investigators at Biofluidica, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Low-cost microfluidic system for detection of CTCs$999,873
N44 · FY2013 · CA
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia$837,994
R44 · FY2019 · CA
Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)$808,983
R44 · FY2015 · CA
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood$798,225
R44 · FY2017 · CA
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood$712,071
R44 · FY2018 · CA
Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)$687,200
R44 · FY2016 · CA
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia$556,708
R44 · FY2020 · CA
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia$348,768
R44 · FY2018 · CA
A microfluidic platform for the high-throughput isolation circulating fetal trophoblasts for non-invasive prenatal testing$291,545
R43 · FY2019 · HD
Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms$286,548
R43 · FY2018 · CA
Parallel and high throughput isolation of cancer cell derived extracellular vesicles$239,138
R43 · FY2018 · CA
CTC Screening Assay to Address Health Disparities in Women with Ovarian Cancer$199,848
R43 · FY2015 · EB
CTC Screening Assay to Address Health Disparities in Women with Ovarian Cancer$199,833
R43 · FY2016 · EB
Low-Cost Microfluidic System for Detection of CTC's$199,517
N43 · FY2010 · CA